Deborah Rudin
Dr.; Assistant / Postdoc in the Liechti Lab and lead of Receptor Profiling at the University of Basel
Data updated
Research Footprint
Deborah Rudin appears in 8 tracked papers (2023–2026), most studied alongside MDMA, DMT and LSD, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants (81 citations).
Frequent co-authors: Matthias Liechti, David Luethi and Andreas Eckert.
Background & Research
Dr. Deborah Rudin is a researcher in the Psychopharmacology group at the University of Basel’s Department of Biomedicine / Pharmaceutical Sciences. Her work appears across controlled human studies of LSD, DMT, MDMA, and related compounds, including bioavailability, acute effects, and receptor profiling. She is associated with Matthias Liechti’s research program, which investigates psychoactive substances in vitro and in humans.
Key Impact
She is part of a leading human psychopharmacology group studying the acute effects, pharmacokinetics, and pharmacology of psychedelics and MDMA in controlled clinical studies.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Deborah Rudin is associated with.